Skip to main content

Table 3 Association of HDAC1 expression with various clinicopathological factors

From: Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

Characteristic All cases HDAC 1 low (IRS 0–4) HDAC 1 intermediate (IRS 6–8) HDAC 1 high (IRS 9–12) P-valueχ 2-test for trends
All cases 208 (100%) 71 (34.1%) 69 (33.2%) 68 (32.7%) --
Histological type      0.17
Ductal carcinoma/Other 176 (100%) 62 (35.2%) 60 (34.1%) 54 (30.7%)  
Lobular carcinoma 28 (100%) 7 (25%) 9 (32.1%) 12 (42.9%)  
Histological grade      0.89
G1 61 (100%) 24 (39.3%) 20 (32.8%) 17 (27.9%)  
G2 90 (100%) 25 (27.8%) 28 (31.1%) 37 (41.1%)  
G3 53 (100%) 20 (37.8%) 21 (39.6%) 12 (22.6%)  
Nodal status      0.23
negative 129 (100%) 48 (37.2%) 42 (32.6%) 39 (30.2%)  
positive 67 (100%) 18 (26.9%) 26 (38.8%) 23 (34.3%)  
pT-Stage      0.88
pT1 116 (100%) 41 (35.3%) 37 (31.9%) 38 (32.8%)  
pT2/pT3 78 (100%) 23 (29.5%) 30 (38.5%) 25 (32%)  
pT4 9 (100%) 4 (44.4%) 2 (22.2%) 3 (33.4%)  
Hormone receptor status      <0.001*
Hormone receptor positive 162 (100%) 46 (28.4%) 54 (33.3%) 62 (38.3%)  
Hormone receptor negative 41 (100%) 22 (53.7%) 15 (36.6%) 4 (9.7%)  
HER2 status      0.71
negative 175 (100%) 60 (34.3%) 58 (33.1%) 57 (32.6%)  
positive 25 (100%) 9 (36%) 9 (36%) 7 (28%)